Clinical trials: Digestive System Cancer
Colorectal Cancer
NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of NB1011 in treating patients who have metastatic or…
- Trial name
- NCT00031616
- Testing
- brivudine phosphoramidate
- Where
- 2 sites in United States
- Sponsor
- NewBiotics
Familial Adenomatous Polyposis
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
2 Year randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of EPA-FFA gastro resistant capsules in FAP.
- Trial name
- NCT03806426
- Testing
- Eicosapentaenoic acid free fatty acid (EPA-FFA)
- Where
- Italy
- Volunteers
- 204 people
- Sponsor
- S.L.A. Pharma AG
Primary Liver Cancer, Hepatocellular Carcinoma
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors
- Conditions
- Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma
- Trial name
- NCT05292443
- Testing
- Observation
- Where
- 5 sites in China
- Sponsor
- Geneplus-Beijing Co. Ltd.
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Carcinoma, Hepatocellular
Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma
This is an open labeled, multiple centers, two countries (Taiwan and Korea) non-comparative phase I trial in patients with hepatocellular carcinoma. In phase I part, a maximum of 18 patients will be recruited in this study.
- Trial name
- NCT02293850
- Testing
- OBP-301
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 18 people
- Sponsor
- Oncolys BioPharma Inc
Hepatocellular Carcinoma
AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma
A phase 1 study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients.
- Trial name
- NCT03971747
- Testing
- AFP Specific T Cell Receptor T Cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai AbelZeta Ltd.
Lung Cancer, Head and Neck Cancer
First-in-human Study of S-588210 (S-488210+S-488211)
The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
- Conditions
- Lung Cancer, Head and Neck Cancer, Bladder Cancer, Esophageal Cancer
- Trial name
- NCT04316689
- Testing
- S-488210, S-488211
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Shionogi
Mouth Diseases, Mouth Ulcers
Safety and Efficacy of RK0202 in Oral Mucositis
The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis in subjects receiving radiation therapy for head and neck cancer.
- Conditions
- Mouth Diseases, Mouth Ulcers, Oral Mucositis, Head and Neck Cancer
- Trial name
- NCT00230191
- Testing
- RK-0202
- Where
- 9 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- RxKinetix
Colorectal Cancer (CRC) Screening
Evaluation of the Performance of the CleanC System-Israel
The Motus GI Colon Cleansing device is intended to facilitate intra-procedural cleaning of a poorly prepared colon by irrigating the colon and evacuating the irrigation fluid and feces.
- Trial name
- NCT02387268
- Testing
- CleanC system
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Motus GI Medical Technologies Ltd
Bile Duct Cancer
Looking At Bile Duct Cancer Patient Experience Patterns in Medical Trials
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical trials, both positive and negative.
- Trial name
- NCT05706974
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Cancer-related Fatigue， Gastric Cancer，Colorectal Cancer，Nano-crystalline Megestrol Acetate，Megestrol Acetate，First-line Treatment
Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
This study is a prospective, randomized, parallel-controlled clinical trial, with the primary objective to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to…
- Trial name
- NCT06830018
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, Standard Treatment
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Screening Colonoscopy, Surveillance Colonoscopy
A Study to Evaluate the Safety and Efficacy of the Use of ME-APDS During Colonoscopy
ME-APDS is a device (software-based with hardware) developed by Magentiq Eye LTD and intended to support the decision of the endoscopist on polyps which appear in the colonoscopy video during the colonoscopy procedure.
- Trial name
- NCT04640792
- Testing
- Screening or Surveillance Conventionall colonoscopy
- Where
- 11 sites in United States, Germany and 2 more
- Volunteers
- 952 people, healthy volunteers welcome
- Sponsor
- Magentiq Eye LTD
Advance Solid Tumors, Colon and Rectal Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
- Conditions
- Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
- Trial name
- NCT07610798
- Testing
- INV-8989
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
- Trial name
- NCT06835569
- Testing
- ALTA3263, cetuximab, mFOLFOX6
- Where
- 14 sites in United States
- Volunteers
- 448 people
- Sponsor
- Alterome Therapeutics, Inc.
Colon Cancer
Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure
This is a study whose focus is on understanding the clinical utility of rectal ultrastructure in detecting colonic neoplasm. The method uses Low-coherence Enhanced Backscattering Spectroscopy (LEBS).
- Trial name
- NCT02730702
- Testing
- LEBS - Low coherence enhanced backscattering
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- American BioOptics, LLC
Pancreatic Cancer
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
This open-label extension study will evaluate the long-term safety and efficacy of oral MNTX in participants with advanced pancreatic cancer (adenocarcinoma) who were previously enrolled in Study SAL-REL-2042 (NCT04083651).
- Trial name
- NCT04151719
- Testing
- Methylnaltrexone bromide (MNTX)
- Sponsor
- Bausch Health Americas, Inc.
MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally…
- Trial name
- NCT06116136
- Testing
- S095029, pembrolizumab 200 mg (KEYTRUDA ®)
- Where
- 49 sites in United States, Australia and 13 more
- Volunteers
- 48 people
- Sponsor
- Servier Bio-Innovation LLC
Biliary Tract Cancer
Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
The primary objective are: To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1. To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed…
- Trial name
- NCT05065957
- Testing
- D07001-softgel capsules + Xeloda (or TS-1), mFOLFOX
- Where
- 5 sites in Taiwan
- Volunteers
- 180 people
- Sponsor
- InnoPharmax Inc.
Carcinoma, Hepatocellular
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.
- Trial name
- NCT00494299
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 75 sites in Japan, South Korea
- Volunteers
- 458 people
- Sponsor
- Bayer
Pancreatic Cancer
Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer
Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology.
- Trial name
- NCT03941457
- Testing
- BiCAR-NK cells (ROBO1 CAR-NK cells)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Asclepius Technology Company Group (Suzhou) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.